Multidrug resistance in amoebiasis patients

Devendra Bansal, Rakesh Sehgal, Yogesh Chawla, Nancy Malla, R. C. Mahajan

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background & objectives: Amoebiasis, caused by Entamoeba sp. a protozoan parasite, is a major public health problem in tropical and subtropical countries. The symptomatic patients are treated by specific chemotherapy. However, there are reports of treatment failure in some cases suggesting the possibility of drug resistance. The present study was therefore planned to assess the presence and expression of mRNA of multidrug resistance (MDR) gene in clinical isolates of Entamoeba histolytica and E. dispar. Methods: Forty five clinical isolates of Entamoeba sp. [E. histolytica (15) and E. dispar (30)] were maintained in polyxenic followed by monoxenic medium. DNA and total RNA were extracted from clinical isolates of Entamoeba sp. and from sensitive strain of E. histolytica (HM1: IMSS) and subjected to polymerase chain reaction (PCR) and multiplex reverse transcription (RT)-PCR techniques. Results: The 344 bp segment of E. histolytica DNA was seen by PCR using primers specific to EhPgp1 in all clinical isolates and sensitive strain of E. histolytica. Over expression of EhPgp1 was observed only in resistant mutant of E. histolytica; however, transcription of EhPgp1 was not seen in any clinical isolates and sensitive strain of E. histolytica. Interpretation & conclusion: The findings of the present study indicate that, so far, drug resistance in clinical isolates of E. histolytica does not seem to be a major problem in this country. However, susceptibility of clinical isolates of E. histolytica against various antiamoebic drugs needs to be investigated for better management.

Original languageEnglish
Pages (from-to)189-194
Number of pages6
JournalIndian Journal of Medical Research
Volume124
Issue number2
Publication statusPublished - 1 Aug 2006
Externally publishedYes

Fingerprint

Amebiasis
Entamoeba histolytica
Polymerase chain reaction
Multiple Drug Resistance
Transcription
Pharmaceutical Preparations
Entamoeba
Chemotherapy
DNA
Public health
Medical problems
Genes
RNA
Drug Resistance
Messenger RNA
MDR Genes
Polymerase Chain Reaction
Multiplex Polymerase Chain Reaction
Treatment Failure
Reverse Transcription

Keywords

  • E. dispar
  • EhPgp1
  • Entamoeba histolytica
  • Multidrug resistance
  • Multiplex RT-PCR

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Bansal, D., Sehgal, R., Chawla, Y., Malla, N., & Mahajan, R. C. (2006). Multidrug resistance in amoebiasis patients. Indian Journal of Medical Research, 124(2), 189-194.

Multidrug resistance in amoebiasis patients. / Bansal, Devendra; Sehgal, Rakesh; Chawla, Yogesh; Malla, Nancy; Mahajan, R. C.

In: Indian Journal of Medical Research, Vol. 124, No. 2, 01.08.2006, p. 189-194.

Research output: Contribution to journalArticle

Bansal, D, Sehgal, R, Chawla, Y, Malla, N & Mahajan, RC 2006, 'Multidrug resistance in amoebiasis patients', Indian Journal of Medical Research, vol. 124, no. 2, pp. 189-194.
Bansal D, Sehgal R, Chawla Y, Malla N, Mahajan RC. Multidrug resistance in amoebiasis patients. Indian Journal of Medical Research. 2006 Aug 1;124(2):189-194.
Bansal, Devendra ; Sehgal, Rakesh ; Chawla, Yogesh ; Malla, Nancy ; Mahajan, R. C. / Multidrug resistance in amoebiasis patients. In: Indian Journal of Medical Research. 2006 ; Vol. 124, No. 2. pp. 189-194.
@article{c9cdcb4a841344ec8c7c26cc7257b92b,
title = "Multidrug resistance in amoebiasis patients",
abstract = "Background & objectives: Amoebiasis, caused by Entamoeba sp. a protozoan parasite, is a major public health problem in tropical and subtropical countries. The symptomatic patients are treated by specific chemotherapy. However, there are reports of treatment failure in some cases suggesting the possibility of drug resistance. The present study was therefore planned to assess the presence and expression of mRNA of multidrug resistance (MDR) gene in clinical isolates of Entamoeba histolytica and E. dispar. Methods: Forty five clinical isolates of Entamoeba sp. [E. histolytica (15) and E. dispar (30)] were maintained in polyxenic followed by monoxenic medium. DNA and total RNA were extracted from clinical isolates of Entamoeba sp. and from sensitive strain of E. histolytica (HM1: IMSS) and subjected to polymerase chain reaction (PCR) and multiplex reverse transcription (RT)-PCR techniques. Results: The 344 bp segment of E. histolytica DNA was seen by PCR using primers specific to EhPgp1 in all clinical isolates and sensitive strain of E. histolytica. Over expression of EhPgp1 was observed only in resistant mutant of E. histolytica; however, transcription of EhPgp1 was not seen in any clinical isolates and sensitive strain of E. histolytica. Interpretation & conclusion: The findings of the present study indicate that, so far, drug resistance in clinical isolates of E. histolytica does not seem to be a major problem in this country. However, susceptibility of clinical isolates of E. histolytica against various antiamoebic drugs needs to be investigated for better management.",
keywords = "E. dispar, EhPgp1, Entamoeba histolytica, Multidrug resistance, Multiplex RT-PCR",
author = "Devendra Bansal and Rakesh Sehgal and Yogesh Chawla and Nancy Malla and Mahajan, {R. C.}",
year = "2006",
month = "8",
day = "1",
language = "English",
volume = "124",
pages = "189--194",
journal = "Indian Journal of Medical Research",
issn = "0971-5916",
publisher = "Indian Council of Medical Research",
number = "2",

}

TY - JOUR

T1 - Multidrug resistance in amoebiasis patients

AU - Bansal, Devendra

AU - Sehgal, Rakesh

AU - Chawla, Yogesh

AU - Malla, Nancy

AU - Mahajan, R. C.

PY - 2006/8/1

Y1 - 2006/8/1

N2 - Background & objectives: Amoebiasis, caused by Entamoeba sp. a protozoan parasite, is a major public health problem in tropical and subtropical countries. The symptomatic patients are treated by specific chemotherapy. However, there are reports of treatment failure in some cases suggesting the possibility of drug resistance. The present study was therefore planned to assess the presence and expression of mRNA of multidrug resistance (MDR) gene in clinical isolates of Entamoeba histolytica and E. dispar. Methods: Forty five clinical isolates of Entamoeba sp. [E. histolytica (15) and E. dispar (30)] were maintained in polyxenic followed by monoxenic medium. DNA and total RNA were extracted from clinical isolates of Entamoeba sp. and from sensitive strain of E. histolytica (HM1: IMSS) and subjected to polymerase chain reaction (PCR) and multiplex reverse transcription (RT)-PCR techniques. Results: The 344 bp segment of E. histolytica DNA was seen by PCR using primers specific to EhPgp1 in all clinical isolates and sensitive strain of E. histolytica. Over expression of EhPgp1 was observed only in resistant mutant of E. histolytica; however, transcription of EhPgp1 was not seen in any clinical isolates and sensitive strain of E. histolytica. Interpretation & conclusion: The findings of the present study indicate that, so far, drug resistance in clinical isolates of E. histolytica does not seem to be a major problem in this country. However, susceptibility of clinical isolates of E. histolytica against various antiamoebic drugs needs to be investigated for better management.

AB - Background & objectives: Amoebiasis, caused by Entamoeba sp. a protozoan parasite, is a major public health problem in tropical and subtropical countries. The symptomatic patients are treated by specific chemotherapy. However, there are reports of treatment failure in some cases suggesting the possibility of drug resistance. The present study was therefore planned to assess the presence and expression of mRNA of multidrug resistance (MDR) gene in clinical isolates of Entamoeba histolytica and E. dispar. Methods: Forty five clinical isolates of Entamoeba sp. [E. histolytica (15) and E. dispar (30)] were maintained in polyxenic followed by monoxenic medium. DNA and total RNA were extracted from clinical isolates of Entamoeba sp. and from sensitive strain of E. histolytica (HM1: IMSS) and subjected to polymerase chain reaction (PCR) and multiplex reverse transcription (RT)-PCR techniques. Results: The 344 bp segment of E. histolytica DNA was seen by PCR using primers specific to EhPgp1 in all clinical isolates and sensitive strain of E. histolytica. Over expression of EhPgp1 was observed only in resistant mutant of E. histolytica; however, transcription of EhPgp1 was not seen in any clinical isolates and sensitive strain of E. histolytica. Interpretation & conclusion: The findings of the present study indicate that, so far, drug resistance in clinical isolates of E. histolytica does not seem to be a major problem in this country. However, susceptibility of clinical isolates of E. histolytica against various antiamoebic drugs needs to be investigated for better management.

KW - E. dispar

KW - EhPgp1

KW - Entamoeba histolytica

KW - Multidrug resistance

KW - Multiplex RT-PCR

UR - http://www.scopus.com/inward/record.url?scp=33749474364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749474364&partnerID=8YFLogxK

M3 - Article

VL - 124

SP - 189

EP - 194

JO - Indian Journal of Medical Research

JF - Indian Journal of Medical Research

SN - 0971-5916

IS - 2

ER -